Hanmi Pharmaceutical Company Limited: Diabetes Mellitus trials

The registry lists 14 Diabetes Mellitus studies with Hanmi Pharmaceutical Company Limited as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 10Phase 2 3Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and ExerciseCompletedNCT03353350Phase 3Results posted
• Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes MellitusStatus unknownNCT03332849Phase 1
• Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes MellitusTerminatedNCT03332836Phase 1
• A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470CompletedNCT02302443Phase 1
• Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesCompletedNCT02081118Phase 2
• A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusStatus unknownNCT02059564Phase 1
• Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesCompletedNCT02057172Phase 2
• Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 10mgCompletedNCT02026817Phase 1
• Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mgCompletedNCT02011633Phase 1
• Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mgCompletedNCT01929512Phase 1
• Single-dose, 2-way Crossover Open Study to Evaluate the Food Effect on the PK of HCP1201 in Healthy VolunteersCompletedNCT01901757Phase 1
• Evaluating a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin CalciumCompletedNCT01775579Phase 1
• A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460ACompletedNCT01724814Phase 1
• Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusCompletedNCT01452451Phase 2